« Back
Home /
Anti-PD-1 (RMP1-14)

Anti-PD-1 (RMP1-14)

Item no.	ICH1132-25MG
Manufacturer	IchorBio
Amount	25 mg
Quantity options	100 mg 1 mg 1 g 25 mg 500 mg 50 mg 5 mg
Category	Oncology Antibodies In Vivo Antibodies By Cell Type Carcinoma Hematology Lymphoma Myelofibrosis Flow Cytometry Western Blot Blocking Functional Assays
Type	Antibody Monoclonal
Format	Liquid
Applications	WB, FC, Blocking, FA
Clone	RMP1-14
Specific against	Mouse (Murine, Mus musculus)
Host	Rat
Isotype	IgG2a
Purity	>95% by SDS-PAGE and HPLC
Citations	Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection Kauffman et al. PSGL-1 Blockade Induces Classical Activation of Human Tumor-Associated Macrophages. Cancer Research Communications 2023 Liang et al. SIX4 Controls STING Expression Enhancing anti-PD-1 Efficacy. bioRxiv Xu et al. One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade. bioRxiv Benguigui et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. 2024, Cancer Cell 42, 253–265 Shyr, C.-R. et al. Evaluating Therapeutic Efficacy of Intravesical Xenogeneic Urothelial Cell Treatment Alone and in Combination with Chemotherapy or Immune Checkpoint Inhibition in a Mouse Non-Muscle-Invasive Bladder Cancer Model. Cancers 2025, 17, 2448. Roichman et al. Dietary Fiber Lacks a Consistent Effect on Immune Checkpoint Blockade Efficacy Across Diverse Murine Tumor Models. Cancer Res 2025 Braun, Lukas M. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell, Volume 43, Issue 2, 269 - 291.e19 Braun LM, Zeiser, R. Protocol to study in vivo organ-specific migration of apoptotic splenocytes in mice with tumor and immune checkpoint inhibitor-induced colitis, STAR Protocols, Volume 6, Issue 2, 2025, 103878. Levin, Sapir et al. Immature monocytic cells within tumors differentiate into immunosuppressive cells in resistant tumors to immunotherapy. iScience, Volume 28, Issue 8, 113141 Patel, A. et al. Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors. Pharmaceutics 2025, 17, 691.
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Alias	Programmed cell death protein 1,Pdcd1,CD279
Shipping Condition	Cool pack
Available
Manufacturer - Applications	Western Blot, Blocking, Flow Cytometry, Functional Assays
Manufacturer - Category	Low Endotoxin, anti-mouse, monoclonal antibody, Cited
Manufacturer - Targets	PD-1
Shipping Temperature	Blue ice
Storage Conditions	anti-PD-1 In Vivo Antibody - Low Endotoxin (RMP1-14) is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -70oC.
Aggregation	Aggregation level ≤ 5%
Formulation	0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Antigen Distribution	Subset of double negative thymocytes, activated T and B cells
Application Notes	Blocking: Clone RMP1-14 antibody has been shown to block the binding of both mouse PD-L1-Ig and mouse PD-L2-Ig to PD-1. For immune checkpoint antibodies 200 ug per mouse per injection is the standard dosage in the literature. For this anti-PD-1 (clone RMP1-14), we suggest to inject 200 ug/mouse ip generally on days 3, 6 and 9, post injection of tumor. Sometime up to six injections depending on the length of the experiment may be required. Each investigator should determine their own optimal working dilution for specific applications.
Background	CD279, also known as programmed death-1 (PD-1) is a 50-55 kD immunoglobulin superfamily member. PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells. The PD-1 ligands, PD-L1 (also known as B7-H1) and PD-L2 (B7-DC), are members of the B7 immunoglobulin superfamily. This RMP1-14 antibody has been reported to block the binding of PD-1 to its ligands (B7-H1 and B7-DC) and to inhibit T cell proliferation and cytokine production.
Concentration	1.0 - 5.0 mg/ml
Endotoxin	≤ 1.0 EU/mg as determined by the LAL method
Manufacturer - Specificity	Anti-PD-1 In Vivo Antibody - Low Endotoxin (RMP1-14) recognizes an epitope on Mouse PD-1
Purification method	This monoclonal antibody was purified using Protein G
Use	Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Immunogen	Mouse PD-1 transfected BHK cells
Related Antibodies	Anti-PD-1 In Vivo Antibody - Ultra Low Endotoxin [RMP1-14] (ICH1132UL)
Isotype Control	Rat IgG2a In Vivo Isotype Control - Low Endotoxin [1-1] (ICH2244)
Buffer	ICH3001-100ml, ICH3002-100ml, ICH3003-100ml

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

ICH1132-25MG-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 25 mg

available

Delivery expected until 2/19/2026

Express Delivery: Save 3 days

Compare

Add to wishlist

Get an offer